The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia
Venetoclax, a BCL-2 inhibitor, has shown promising efficacy in Waldenström macroglobulinemia (WM) patients. Here, Jorge Castillo, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the results of the Phase II study (NCT02677324) evaluating the safety and efficacy of venetoclax monotherapy in previously treated WM patients. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Castillo reveals that venetoclax is well tolerated, producing high levels of response in patients with symptomatic, previously treated WM, including those exposed to BTK inhibitors.
